On Dec. 14, 2012, FDA approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. == References ==
References
External links
Shire Pharmaceuticals Agrylin/Xagrid website for international visitors
Shire Pharmaceuticals Xagrid website for UK visitors
AOP Orphan Pharmceuticals website